undamentalytics Newsletter
Sign in

Proqr Therapeutics N.V. (PRQR) stock

Add to watchlist

Add holding +

NASDAQ: PRQR Nasdaq Biotechnology Next results ~November 5, 2026

D Fundamentals grade

Proqr Therapeutics N.V. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Proqr Therapeutics N.V. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Proqr Therapeutics N.V. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders2 buying, 0 selling5 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds37 adding, 22 cuttingOf 15 active managers that changed their stake, 9 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Proqr Therapeutics files

Where Proqr Therapeutics N.V. stands after its latest Filing

Revenue for the twelve months was $18m, down 12.1% on a year earlier, against growth of 190.3% a quarter earlier. Free-cash-flow margin rose to -338.3% from -1984.7% a year earlier. Operating margin widened to -273.1% from -4285.4%. The diluted share count is up 22.4% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 2 of our 3 financial-health checks.

Our model value for Proqr Therapeutics is under review, so past values are not shown until it is resolved.

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Proqr Therapeutics N.V.'s trailing-twelve-month revenue fell 12.1% year on year, with a free-cash-flow margin of -338.3%. Where it lags: change in growth rate of -202.4pp ranks 165 of 172 biotechnology companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to -12.1% (-202.4pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.1bn.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Revenue shrinking. Revenue fell 12.1% over the last 12 months.
  • Growth slowing. The growth rate is 202.4 points lower than a quarter earlier.
  • Loss-making. Operating margin is -273.1%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 112.0 points on a year ago.
  • Burning cash. Free cash flow was -338.3% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 25.2% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.

Latest results

Earnings per share
-$0.09 against an average estimate of -$0.18: beat by 49.5%
Next report
November 5, 2026

Proqr Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-5.0%
  • 1 week+6.5%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$18M
Operating margin
-273.1%
Net margin
-265.2%
EPS (TTM, diluted)
$-0.45

Growth

Revenue growth
−12.1%
Change in growth rate
−202.4 pts
Share count change
+22.4%

Cash

Free cash flow (TTM)
-$60.8M
FCF margin
-338.3%
Stock pay % of revenue
25.2%

News & updates

Updated November 2, 2026

Company announcements, filed results and changes that matter to shareholders.

No recent updates are available for PRQR from the sources we follow. See filings →

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Proqr Therapeutics N.V. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Proqr Therapeutics N.V. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.2 ~$0.5–$1.6 Left out: out of range vs price (0.16x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Proqr Therapeutics N.V. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, before the open.

Analysts' consensus

No analyst estimates are published for Proqr Therapeutics N.V.: too few analysts cover it.

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.18 −$0.09 +49.5%
Mar 2026 −$0.18 −$0.15 +14.6%
Dec 2025 −$0.12 −$0.09 +21.2%
Sept 2025 −$0.17 −$0.12 +29.1%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

9 analysts, Nov 2026
Buy9100%
Hold00%
Sell00%

Monthly trend

  1. Nov 2026189
  2. Oct 2026189
  3. Sep 2026189

Counts of recommendations published by analysts covering Proqr Therapeutics N.V., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
2.7%
of tradable shares
Days to cover
3.74
at average volume
Short interest, 1 month
+21%
to October 15, 2026
Held by institutions
54%
of shares
Held by insiders
17.5%
of shares
Employees
186
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Price behaviour

52-week range
Not enough history
From 52-week high
—
vs 50-day average
—
vs 200-day average
—
Volatility (1 year)
—
Beta vs S&P 500
—

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Proqr Therapeutics N.V. in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Proqr Therapeutics N.V.
$0 $10M $20M $30M FY21 Q4 FY22 Q4 FY23 Q4 FY24 Q4 FY25 Q4 Revenue (TTM), FY21 Q4: $1.6M Revenue (TTM), FY22 Q4: $3.8M Revenue (TTM), FY23 Q4: $7M Revenue (TTM), FY24 Q4: $20.5M Revenue (TTM), FY25 Q4: $18M $18M

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY21 Q4 $1.6M
FY22 Q4 $3.8M
FY23 Q4 $7M
FY24 Q4 $20.5M
FY25 Q4 $18M
Revenue growth, TTM YoY Proqr Therapeutics N.V.
-100% 0% 100% 200% FY22 Q4 FY23 Q4 FY24 Q4 FY25 Q4 Revenue growth, TTM YoY, FY22 Q4: 139.7% Revenue growth, TTM YoY, FY23 Q4: 86.1% Revenue growth, TTM YoY, FY24 Q4: 190.3% Revenue growth, TTM YoY, FY25 Q4: -12.1% -12.1%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue growth, TTM YoY
FY22 Q4 139.7%
FY23 Q4 86.1%
FY24 Q4 190.3%
FY25 Q4 -12.1%
Operating margin (TTM) Proqr Therapeutics N.V.
-6000% -4000% -2000% 0% FY21 Q4 FY22 Q4 FY23 Q4 FY24 Q4 FY25 Q4 Operating margin (TTM), FY21 Q4: -4285.4% Operating margin (TTM), FY22 Q4: -1813.0% Operating margin (TTM), FY23 Q4: -489.1% Operating margin (TTM), FY24 Q4: -161.2% Operating margin (TTM), FY25 Q4: -273.1% -273.1%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY21 Q4 -4285.4%
FY22 Q4 -1813.0%
FY23 Q4 -489.1%
FY24 Q4 -161.2%
FY25 Q4 -273.1%
FCF margin (TTM) Proqr Therapeutics N.V.
-2000% -1000% 0% 1000% FY21 Q4 FY22 Q4 FY23 Q4 FY24 Q4 FY25 Q4 FCF margin (TTM), FY21 Q4: -1984.7% FCF margin (TTM), FY22 Q4: -1925.9% FCF margin (TTM), FY23 Q4: 309.7% FCF margin (TTM), FY24 Q4: -200.0% FCF margin (TTM), FY25 Q4: -338.3% -338.3%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period FCF margin (TTM)
FY21 Q4 -1984.7%
FY22 Q4 -1925.9%
FY23 Q4 309.7%
FY24 Q4 -200.0%
FY25 Q4 -338.3%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 20-F. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025
Income
Revenue 2 4 7 20 18
EBITDA −65 −66 −32 −30 −46
Operating income −68 −69 −34 −33 −49
Net income −72 −68 −30 −30 −48
Diluted EPS −$1.12 −$0.95 −$0.38 −$0.35 −$0.45
Growth (year on year)
Revenue — +139.7% +86.1% +190.3% −12.1%
Margins
EBITDA margin <−999% <−999% −450.5% −146.6% −256.1%
Operating margin <−999% <−999% −489.1% −161.2% −273.1%
Net margin <−999% <−999% −431.7% −146.9% −265.2%
Free-cash-flow margin <−999% <−999% 309.7% −200.0% −338.3%
Cash flow
Cash from operations −31 −72 23 −39 −60
Capital spending 1 1 1 2 1
Free cash flow −31 −73 22 −41 −61
Stock-based pay 7 3 3 3 5
Free cash flow after stock pay −39 −76 18 −44 −65
Balance sheet
Cash 212 101 132 155 108
Total debt 50 7 5 5 6
Net debt (negative = net cash) −162 −94 −127 −150 −103
Diluted shares 64m 72m 81m 86m 105m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 3 checks passed · December 31, 2025
What it owns · $132m
Short-term assets $118mLonger-term assets $15m
What it owes, and who funded it · $132m
Short-term liabilities $38mLonger-term liabilities $36mShareholders' equity $58m
  • Short-term assets cover short-term liabilities $118m of assets due within a year against $38m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $118m short-term assets against $36m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$49m against $1m of interest.

From Proqr Therapeutics N.V.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+22.4%
year over year
R&D spending
281.2%
of revenue
Days sales outstanding
162 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated PRQR CTMX CELU SCYX KROS ALEC Median
Revenue, last 12 months $18m $18m $19m $19m $15m $14m $56m
Revenue growth, last 12 months −12.1% −87.0% −58.1% 489.8% −93.6% −82.9% 12.6%
Revenue growth, 3-year average — −38.7% 7.2% −47.9% — −48.6% 13.7%
Revenue growth, latest quarter — −92.4% −5.3% −82.8% −100.0% −57.8% 10.2%
Gross margin — — 19.2% 26.0% — — 82.9%
Operating margin −273.1% −476.2% −264.3% −117.6% −682.3% −912.4% −189.4%
Operating margin, 3-year average — −146.9% −204.2% −592.1% <−999% −472.3% −363.5%
Net margin −265.2% −435.2% −245.7% −53.3% −559.2% −850.1% −169.8%
Cash from operations / revenue −331.9% −450.3% −47.8% −69.3% −322.7% <−999% −168.0%
Free-cash-flow margin −338.3% −450.7% −80.1% −69.3% −326.1% <−999% −162.4%
Free-cash-flow margin, 3-year average — −192.6% −50.3% −304.8% <−999% −600.8% −310.0%
Stock pay / revenue 25.2% 55.4% 66.5% 12.3% 153.8% 120.9% 20.0%
Change in share count 22.4% 88.7% 24.7% 1.9% −31.6% 9.7% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth -12.1% 12.6% 119 of 172
Change in growth rate Growth -202.4pp -0.1pp 165 of 172
Operating margin Profitability -273.1% -189.4% 101 of 175
Net margin Profitability -265.2% -157.3% 106 of 180
Free-cash-flow margin Cash generation -338.3% -145.4% 119 of 176
Stock pay as % of revenue Cash generation 25.2% 19.2% 98 of 179
Change in share count Balance sheet 22.4% 7.9% 118 of 156
Days sales outstanding Balance sheet 162 days 75 days 89 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$113M
Institutions reporting
69
Shares held vs prior quarter
▲ 73.4%
Positions opened / closed
13 / 11

Top buyers and sellers, Q2 2026: 37 institutions bought and 22 sold ; the biggest buyer was Aberdeen Group PLC (+5.6M shares) and the biggest seller Sio Capital Management, LLC (−2.0M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Adage Capital Partners Gp, L.L.C. $16.8M 9.0M 14.9% ▲ 44.2%
Aberdeen Group PLC $16.6M 8.9M 14.7% ▲ 169.3%
Affinity Asset Advisors, LLC $10.3M 5.5M 9.2% ▲ 125.9%
Privium Fund Management B.V. $10.3M 5.5M 9.1% ▲ 1.0%
Ikarian Capital, LLC $6.4M 3.4M 5.7% ▲ 129.6%
Woodline Partners LP $6.1M 3.3M 5.4% New
Heights Capital Management, Inc $5.1M 2.8M 4.6% New
Morgan Stanley $3.3M 1.8M 2.9% ▲ 36.0%
Sphera Funds Management Ltd. $3.3M 1.8M 2.9% New
Kynam Capital Management, LP $2.9M 1.6M 2.6% 0.0%
Dafna Capital Management LLC $2.8M 1.5M 2.5% ▼ 2.4%
Squadron Capital Management LLC $2.8M 1.5M 2.5% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Proqr Therapeutics N.V.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $1.3M 5 trades by 2 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $1.3M net buying
Insider Date Trade Shares Price Value
De Boer Daniel Anton Chief Executive Officer July 31, 2026 Buy 200,000 $1.77 $354,000
Filius Bart Director July 17, 2026 Buy 150,000 $1.72 $258,000
De Boer Daniel Anton Chief Executive Officer July 9, 2026 Buy 150,000 $1.74 $261,000
De Boer Daniel Anton Chief Executive Officer July 7, 2026 Buy 150,000 $1.59 $238,500
Filius Bart Director June 26, 2026 Buy 150,000 $1.54 $231,000

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Proqr Therapeutics N.V. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Proqr Therapeutics N.V. in brief

What does Proqr Therapeutics N.V. do?
Proqr Therapeutics N.V. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Proqr Therapeutics N.V.'s stock ticker?
Proqr Therapeutics N.V. trades under the ticker PRQR on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Proqr Therapeutics N.V.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Proqr Therapeutics N.V. reported revenue of $18M, 12.1% lower than a year earlier, according to its SEC filings.
What is Proqr Therapeutics N.V.'s free cash flow?
Proqr Therapeutics N.V.'s free-cash-flow margin is -338.3% of revenue over the trailing twelve months, ranking 119 of the 176 biotechnology companies we cover.
Who are Proqr Therapeutics N.V.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Adage Capital Partners Gp, L.L.C., Aberdeen Group PLC and Affinity Asset Advisors, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Who are Proqr Therapeutics N.V.'s competitors?
In our Biotechnology peer group, the companies closest to Proqr Therapeutics N.V. are Cytomx Therapeutics, Inc., Celularity Inc, Scynexis Inc, Keros Therapeutics, Inc. and Alector, Inc. The side-by-side comparison below sets their revenue, margins and growth against Proqr Therapeutics N.V.'s.
Are insiders buying or selling Proqr Therapeutics N.V. stock?
Over the last 12 months, Proqr Therapeutics N.V.'s directors and officers reported 5 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Proqr Therapeutics N.V.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Proqr Therapeutics N.V. announces its own schedule.